Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2026-01-02 @ 12:44 AM
Study NCT ID:
NCT02919969
Status:
COMPLETED
Last Update Posted:
2023-06-12
First Post:
2016-09-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab in Metastatic Anal Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-10-11
Start Date Type:
ACTUAL
Primary Completion Date:
2021-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03
Completion Date Type:
ACTUAL
First Submit Date:
2016-09-02
First Submit QC Date:
None
Study First Post Date:
2016-09-30
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2023-02-23
Results First Submit QC Date:
None
Results First Post Date:
2023-06-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-05-17
Last Update Post Date:
2023-06-12
Last Update Post Date Type:
ACTUAL